Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUINTESSENTIAL-2: Arlocabtagene Autoleucel vs Standard Regimens in Relapsed or Refractory Multiple Myeloma
jRCT2053250007Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Arlocabtagene autoleucel with Standard of care (DPd or Kd) (2 arms). Primary endpoints: Progression-free survival (PFS) and Minimal residual disease (MRD) negativity in complete response (CR). Started May 2025; status: recruiting.
02
Drugs
arlocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2053250007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053250007.